Understanding and managing side effects of peptide receptor radionuclide therapy for neuroendocrine tumors | Research

The takeaway

PRRT is generally well-tolerated for neuroendocrine tumors, but clinicians must recognize acute, subacute, and long-term toxicities and identify high-risk patients to optimize safety and outcomes.

Well-tolerated overall
Most PRRT side effects are transient, but awareness of kidney, bone marrow, and hormonal toxicities is critical for clinicians managing neuroendocrine tumor patients

What the researchers found

PRRT toxicities are stratified into acute (nausea, hormone-related crises), subacute (bone marrow suppression, kidney effects), and long-term (renal impairment, myelodysplastic syndrome). Most side effects are transient, but awareness of high-risk factors is essential for prevention and early management.

Why it matters

As PRRT becomes more widely used for neuroendocrine tumors, clinicians need practical guidance on managing its toxicity profile. Understanding risk factors allows for patient selection optimization and proactive toxicity prevention, maximizing the benefit-to-risk ratio of this peptide-based therapy.

The numbers in context

Toxicities stratified by onset: acute (during/shortly after), subacute (weeks to months), and long-term (months to years). Reviews kidney toxicity, hematological toxicity, and rare secondary malignancies.

How the study worked

Comprehensive narrative review of toxicity data from PRRT clinical experience, including risk factor identification, management strategies, and recent advances in toxicity prediction and prevention.

Who was studied

Neuroendocrine tumor patients receiving PRRT

What this study cannot tell us

Narrative review without systematic methodology or meta-analysis of toxicity rates. Toxicity profiles may vary with different radionuclides and peptide ligands. Risk factor evidence comes largely from retrospective analyses.

How to read the evidence

Narrative review synthesizing clinical experience and published toxicity data. Provides practical clinical guidance but lacks systematic quantification of toxicity rates.

When this study was published

Published in 2025; includes recent advances in PRRT toxicity prediction and management.

The bigger picture

PRRT represents one of the most successful examples of peptide-targeted therapy in oncology. As the field expands to treat more tumor types and develop next-generation radiopeptides, understanding and managing toxicity becomes increasingly critical for safe, widespread clinical adoption.

Questions still open

Can predictive biomarkers reliably identify patients at highest risk for PRRT-related kidney or bone marrow toxicity?
How do next-generation radiopeptides (alpha-emitters) compare in toxicity profile to current lutetium-177 PRRT?
Could combination therapies (PRRT + immunotherapy) alter the toxicity landscape?

Common questions

What are the main side effects of PRRT?

The most common side effects include nausea during infusion (acute), temporary drops in blood cell counts (subacute), and potential kidney function decline with repeated treatments (long-term). Most acute side effects resolve on their own. Serious long-term effects like myelodysplastic syndrome are rare but require monitoring.

How safe is PRRT compared to other cancer treatments?

PRRT is generally well-tolerated compared to conventional chemotherapy, with fewer and milder side effects in most patients. It specifically targets tumor cells expressing somatostatin receptors, reducing damage to healthy tissue. However, kidney and bone marrow monitoring is essential throughout treatment.

Read the original research

Toxicity manifestations encountered in peptide receptor radionuclide therapy setting.

Journal of neuroendocrinology, 37(3), e13464

View on PubMed ↗Publisher’s paper ↗

Citation

Parghane, Rahul V; Basu, Sandip. (2025). Toxicity manifestations encountered in peptide receptor radionuclide therapy setting.. Journal of neuroendocrinology, 37(3), e13464. https://doi.org/10.1111/jne.13464